Regeneron Pharmaceuticals' Share-based Compensation fell 1810.12% to $249.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $993.7 million, marking a year-over-year increase of 110.91%. This contributed to the annual value of $993.7 million for FY2025, which is 110.91% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Share-based Compensation stood at $249.3 million for Q4 2025, which was down 1810.12% from $237.0 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Share-based Compensation ranged from a high of $304.4 million in Q4 2024 and a low of $130.9 million during Q1 2021
Its 5-year average for Share-based Compensation is $209.4 million, with a median of $224.2 million in 2024.
Its Share-based Compensation has fluctuated over the past 5 years, first surged by 5506.17% in 2021, then plummeted by 1810.12% in 2025.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Share-based Compensation stood at $188.4 million in 2021, then rose by 23.14% to $232.0 million in 2022, then increased by 3.62% to $240.4 million in 2023, then rose by 26.62% to $304.4 million in 2024, then fell by 18.1% to $249.3 million in 2025.
Its last three reported values are $249.3 million in Q4 2025, $237.0 million for Q3 2025, and $251.7 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value